Castle Biosciences reaffirms FY2023 revenue guidance of $170-180M and 2025 targets

CASTLE BIOSCIENCES INC

Reaffirms FY2023 total revenue guidance of $170-$180M.
Reaffirms 2025 total revenue target of $255-$330M.
Reaffirms target to achieve net operating cash flow positivity by 2025.

item 7.01

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-23-000097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.